Form 4: Bioadaptives Director Receives Preferred Stock Compensation

Mark P. Frissora, a director at Bioadaptives, Inc., was granted 1,506 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Director Mark P. Frissora of Bioadaptives, Inc. (BDPT) acquired 1,506 shares of Series D Convertible Preferred Stock on September 1, 2025.
• These shares were issued as compensation for his board services, as per an agreement dated February 3, 2025.
• Each preferred share is convertible into 100 shares of common stock, implying a potential conversion of 150,600 common shares from this specific grant.
• Conversion is subject to a 10% beneficial ownership limitation and cannot occur until six months after the issuance date (March 1, 2026), except in case of liquidation.
• Each Series D Convertible Preferred Stock share carries 100 votes on company matters.
• Following this transaction, Mr. Frissora directly beneficially owns a total of 50,007 shares of Series D Convertible Preferred Stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider compensation, which is generally a positive sign of director commitment, but does not indicate significant operational news. The preferred stock structure adds complexity.

Positives

• Issuance of preferred stock as compensation aligns director interests with long-term company performance.
• The significant voting rights (100 votes per preferred share) provide substantial influence to preferred shareholders, potentially stabilizing governance.

Negatives

• The 10% beneficial ownership limitation on conversion could restrict immediate liquidity or full conversion for the director.
• A six-month lock-up period before conversion limits the director's ability to immediately realize value from the compensation.

Risks

• Potential future dilution risk for existing common shareholders if a significant number of preferred shares are converted into common stock.
• The complex structure of preferred stock (conversion ratio, voting rights, limitations) can be less transparent than direct common stock grants.

Future Outlook

The conversion of the Series D Convertible Preferred Stock into common stock is subject to a six-month waiting period from the issuance date, with the right to convert not expiring.

Management Comments

• The Series D Convertible Preferred Stock was issued as compensation for board services pursuant to a Board of Directors Agreement dated February 3, 2025.

Industry Context

The use of convertible preferred stock as executive or director compensation is a common practice, particularly in smaller or growth-oriented companies, to align long-term interests while managing immediate cash outflow. It provides a mechanism for insiders to gain equity exposure with specific terms regarding voting rights and conversion.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from the conversion of preferred stock into common stock. The significant voting rights of preferred shares could concentrate voting power.
• Director (Mark P. Frissora): Receives equity compensation, aligning his interests with the company's long-term performance, but with conversion restrictions.

Next Steps

• The Series D Convertible Preferred Stock will become convertible into common stock six months after the issuance date (March 1, 2026).

Key Dates

Recommendation

This Form 4 filing details a routine compensation event for a director, involving the issuance of convertible preferred stock. While it indicates continued director involvement and alignment of interests, it does not provide new operational or financial information that would warrant a change in investment thesis. The potential for future dilution from conversion is noted, but the immediate impact is minimal. Investors should 'hold' and await further operational updates or financial results.

Keywords

Bioadaptives, BDPT, Form 4, Insider Transaction, Director Compensation, Preferred Stock, Convertible Securities, Mark P. Frissora, Corporate Governance